Academic researchers, clinicians, healthcare entrepreneurs and investors feature in the first announcement for Melbourne’s psychedelic medicine symposium, with major keynote...
The three-day conference, hosted by entrepreneur Dave Asprey, brings together researchers, clinicians and business leaders to discuss psychedelic therapies, neuroscience...
With six months to go until the inaugural PRS27 Psychedelic Roundtable Symposium, Psychedelics.media has announced that early bird tickets are...
For much of the past decade, the modern psychedelic renaissance has been accompanied by an unusually powerful media narrative. Drugs...
Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to...
New Zealand has authorised two psychiatrists to prescribe pharmaceutical-grade MDMA as part of supervised treatment for adults with post-traumatic stress...
With six weeks to go until SCALE 2026, the international mental health and psychedelic medicine community is preparing to gather...
The psychedelic medicine conference circuit is expanding as the field moves from clinical research towards treatment, regulation and healthcare delivery....
As psychedelic-assisted therapy moves from research into clinical practice in Australia, the organisations building the infrastructure around the sector are...
Australian psychedelic biotechnology company Entropy Neurodynamics (ASX: ENP) has secured Human Research Ethics Committee (HREC) approval to begin what it...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
